ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Time to let AD,PD,ALS platform go to Big Pharma

<< Previous

Bullboard Posts

Next >>

Comment by FarmerBettyon Nov 25, 2022 1:09pm

181 Views

Post# 35128524

RE:RE:Time to let AD,PD,ALS platform go to Big Pharma

You would have to get that valuation from the company, they should know? There presentation quotes
" Based on reports for Lecanemab and a Promis 2018 commercial analysis PMN310 opportunity >$1B"

There filings indicate a potential combination of drugs for ALS, mentioning Intrabody development would involve a partner with gene therapy expertise. Way out of Promis's league, complex need a lot of HP for ALS and AD if they want it to move ahead to clinic.

Alzheimers phase 1 safety not going to tell anything that others don't know. How many amyloid phase 1 monoclonal antibody studies have failed?

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Nov. 14, 2024